Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | DBH | P09172 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696351 | 0.92 | CYP2D6 (0.45) | CYP2D6TSHRCYP2C19HIF1AKCNH2 | |
| SCHEMBL697415 | 0.87 | CYP2D6 (0.45) | CYP2D6TSHRCYP2C19HIF1AKCNH2 | |
| SCHEMBL697652 | 0.86 | KCNH2 (0.40) | CYP2D6TSHRCYP2C19HIF1AKCNH2 | |
| SCHEMBL697205 | 0.85 | TDP1 (0.44) | CYP2D6TSHRCYP2C19HIF1AKCNH2 | |
| SCHEMBL697336 | 0.84 | BRD4 (0.49) | CYP2D6TSHRCYP2C19HIF1AKCNH2 | |
| SCHEMBL697360 | 0.83 | FSCN1 (0.44) | KCNH2DBHBRD4TDP1 | |
| SCHEMBL696426 | 0.83 | CYP2D6 (0.45) | CYP2D6TSHRCYP2C19HIF1AKCNH2 | |
| SCHEMBL698656 | 0.82 | KCNH2 (0.42) | CYP2D6TSHRCYP2C19HIF1AKCNH2 | |
| SCHEMBL697196 | 0.82 | ADRA2C (0.39) | CYP2D6TSHRCYP2C19HIF1AKCNH2 | |
| SCHEMBL697585 | 0.82 | ADRA2C (0.53) | TSHRP2RX7ADRA2CTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | CYP2D6 15/4885TSHR 3443/4885CYP2C19 16/4885 |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | CYP2D6 15/4885TSHR 3443/4885CYP2C19 16/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | CYP2D6 15/4885TSHR 3443/4885CYP2C19 16/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | CYP2D6 15/4885TSHR 3443/4885CYP2C19 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.